Herring, R Shojaee-Moradie, F Garesse, R Stevenage, M Jackson, N Lucy, C Fielding, BA Umpleby, A Russell-Jones, DL Davies, M The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes Science & Technology;Life Sciences & Biomedicine;Endocrinology & Metabolism 2020-05-13
    https://figshare.le.ac.uk/articles/conference_contribution/The_metabolic_effects_of_an_SGLT2_inhibitor_dapagliflozin_during_a_period_of_acute_insulin_withdrawal_and_development_of_ketoacidosis_in_people_with_type_1_diabetes/10211429